🏛️ Verified NIH Record • Updated 2026-07-30
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (NCT03383458)
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0081 — Anniston, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (184 Sites)
Showing the first 25 of 184 sites.
- Local Institution - 0081 — Anniston, Alabama
- Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
- Arizona Oncology Associates, PC - HOPE — Tucson, Arizona
- Local Institution - 0135 — Los Angeles, California
- Local Institution - 0088 — Palo Alto, California
- Local Institution - 0085 — San Francisco, California
- Local Institution - 0235 — Aurora, Colorado
- Local Institution - 0267 — Miami, Florida
- Sylvester Comprehensive Cancer Center/ UMHC — Miami, Florida
- Local Institution - 0163 — Tampa, Florida
- Local Institution - 0009 — Atlanta, Georgia
- Local Institution - 0025 — Westwood, Kansas
- Local Institution - 0086 — New Orleans, Louisiana
- University of Michigan — Ann Arbor, Michigan
- Minnesota Oncology Hematology, P.A. — Minneapolis, Minnesota
- Local Institution - 0209 — St Louis, Missouri
- Local Institution - 0075 — New York, New York
- Local Institution - 0208 — New York, New York
- Local Institution - 0045 — New York, New York
- Local Institution - 0219 — White Plains, New York
- MetroHealth Medical Center — Cleveland, Ohio
- Local Institution - 0206 — Portland, Oregon
- Local Institution - 0272 — Austin, Texas
- Local Institution - 0270 — Dallas, Texas
- Local Institution - 0156 — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma
- TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
- TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
- Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona
Explore by condition: All Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.